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Summary The recent use of interleukin 2 (IL-2) and interleukin 4 (IL-4) single cytokine modified tumour cells
in rodent models has demonstrated a potential use of these cytokines to produce autologous cancer cell
vaccines. Here we compare the potential therapeutic benefit of transduction with IL-2 or IL-4 alone, and
combined IL-2+IL-4 in B16F1O cells, a murine malignant melanoma ofpoor immunogenicity. Transduction of
B16F1O cells (MHC class I and II negative) to express either IL-2 or IL-4 alone delays the formation of
tumours, IL-4 being more effective than IL-2. However, combined expression of IL-2+IL4 reduces
tumorigenicity more than either cytokine alone. The eventual formation of tumours may result from loss of
gene expression, and preliminary results suggest methylation of the retroviral long terminal repeat (LTR),
rather than loss of the transduced DNA sequences. Histological examination of tumours expressing either IL-2
or IL-4 alone shows a non-specific inflammatory reaction with an increased tissue infiltrate ofimmune effectors
(monocytes/macrophages, lymphocytes, granulocytes) localised around the tumour. In comparison, when cells
expressing combined IL-2+IL-4 were injected there were more granulocytes present, and perhaps more
importantly, these were mainly localised within the tumour. The benefit of combined IL-2+IL-4 expression
results from a local rather than systemic effect as the growth of tumours from cells expressing IL-2 or IL-4
alone injected at distant sites was comparable with a single inoculation ofcells expressing either cytokine alone.
However, when cells expressing single cytokines IL-2 or IL-4 were mixed and injected at the same site, in
comparison with the clonal population of cells expressing combined IL-2+IL-4, tumour growth was
characteristic of IL-4 alone rather than IL-2+IL-4. Treatment ofestablished tumours with a single injection of
lethally irradiated tumour cells expressing IL-2 +IL-4 was sufficient to either reject tumours, or at least delay
further tumour development. Furthermore, treatment stimulated an initial non-specific immune reaction that
lead to a systemic immunity. Lethally irradiated wild-type cells were also successful in treating some established
tumours, although this did not induce any systemic immunity. However, although successful in treatment
studies, neither wild-type nor combined IL-2+IL-4 expressing cells were able to vaccinate animals against a
subsequent challenge with live wild-type tumour. These results indicate a potential therapeutic benefit with the
use of combination IL-2+IL-4 transduction of autologous cancer cells.
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The early observations in rodent models that the immuno-
logical response ofhost to tumour challenge could be affected
by prior exposure to the tumour suggested the possibility of a
specific host anti-tumour response (Klein et al., 1960; Hewitt
et al., 1976). Such studies led to the use of autologous cancer
cells alone, and in combination with non-specific immuno
stimulants (bacille Calmette-Guerin, Corynebacterium par-
vum), as vaccines to augment anti-tumour immunity.
However, these strategies were only occasionally beneficial
(Oettgen and Old, 1991). Despite this lack of earlier success,
recent studies involving the use of genetically modified
tumour cells in rodent models have raised new possibilities
for the potential of autologous cancer cell vaccines.
For autologous cancer cells to be of benefit in the
treatment of human malignant disease, the tumour cells
must be rendered more immunogenic to stimulate an anti-
tumour immunity that results in systemic protection against
further tumour growth. Although a number of different gene
therapy strategies have been employed, including transduc-
tion with recombinant viral antigens (Fearon et al., 1988
Sugiura et al., 1988), MHC molecules (Wallich et al., 1985)
and immune co-stimulators (e.g. B7.1, B7.2, Baskar et al.,
1993; Li et al., 1994), the most popular to date has been
transduction of tumour cells to express different cytokines.
Using various rodent models these studies have demonstrated
that transduction of tumour cells with genes for IL-2 (Fearon
et al., 1990; Gansbacher et al., 1990a; Patel et al., 1993), IL-4
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(Li et al., 1990; Golumbek et al., 1991; Patel et al., 1993), IL-
6 (Porgador et al., 1992), IL-7 (Aoki et al., 1992), interferon
gamma (y-IFN, Watanabe et al., 1989; Gansbacher et al.,
1990b; Porgador et al., 1993), tumour necrosis factor alpha
(TNF-a, Blankenstein et al., 1991; Teng et al., 1991),
granulocyte colony-stimulating factor (G-CSF, Colombo et
al., 1991) and granulocyte-macrophage colony-stimulating
factor (GM-CSF, Dranoff et al., 1993) can significantly
reduce tumorigenicity in syngeneic hosts. Of perhaps greater
importance, tumour cells modified to express such cytokines
can also induce systemic immunity as mice vaccinated with
transduced cells have been shown to reject a subsequent
challenge of parental (non-transduced) cells, and in some
cases an established tumour.
These studies have produced encouraging results, but they
also indicate that it will be of critical importance to identify
which cytokines and combinations of cytokines are best able
to stimulate an anti-tumour response. Furthermore, these
studies have clearly indicated a relationship between levels of
transduced cytokine gene expression and therapeutic benefit.
However, for a clinical application, whereas autologous
tumour cells expressing high levels of the cytokine transgene
are desirable, this may be difficult to achieve in practice.
Transduction of tumour cells to express multiple cytokine
genes is more feasible than obtaining clones of a high
transgene expression. A synergistic action between cytokines
would therefore potentially provide a more feasible option
for clinical application. Despite this, no studies have
examined the effects of transduction with more than one
cytokine, although some have directly compared the effects of
different single cytokines in the same model (Dranoff et al.,
1993; Patel et al., 1993). An alternative strategy may be toIL-2+1L-4 gene therapy of B16 melanoma
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transduce tumour cells with a single cytokine gene and
administer further cytokines systematically. However,
despite the potential problems of systemic toxicity (eg.
with IL-2), it is important to establish whether such an
approach would prove as efficacious as combined cytokine
gene transduction.
Owing to the central role they play in immune responses,
we have chosen in this study to examine IL-2 and IL-4. To
compare the therapeutic benefit of combined expression of
IL-2+IL-4 with that of either IL-2 or IL-4 alone, we have
used retroviral vectors to produce IL-2, IL-4 and IL-2+IL-4
cytokine-expressing cell lines from the poorly immunogenic,
non-metastasising murine malignant melanoma B16F1O. The
cell lines produced were evaluated in vivo using tumorigeni-
city and treatment studies. Other reported studies have
compared the effects of varying levels of single cytokine
expression on tumour growth in vivo, however, we have
chosen to use clonal populations of transduced cells where
the levels of IL-2 were approximately equal, and the levels of
IL-4 were approximately equal, to examine the benefit of
combined IL-2+IL-4 transduction with that of either IL-2,
or IL-4 alone.
Materials and Methods
Cell lines
Murine B16F1O cells are a non-metastasising subclone of the
spontaneously arising B16 melanoma (Fidler, 1975; MHC
class I and II negative), and are reported to be poorly
immunogenic as defined by the relative lack of host response
to live tumour challenge following prior vaccination with
lethally irradiated wild-type cells. B16F1O cells were grown
in vitro as adherent monolayers in RPMI-1640 supplemented
with 10% fetal calf serum (FCS). The amphotropic
retroviral packaging cell lines PA317 (Miller and Butti-
more, 1986) and GP+envAM12 (Markowitz et al., 1988)
were grown in vitro as adherent monolayers in Dulbecco's
modified Eagle medium (DMEM) with 10% newborn calf
serum (NCS).
Vectors and infection protocol
The producer cell lines GP+envAMI2-pBabeNeo-murine.IL-
2 and GP +envAM12-pBabePuro-murine.IL-4 were a kind
gift from Dr Mary Collins (Institute of Cancer Research,
London); the pBabe vectors (Morgenstern and Land, 1990)
were generated by Dr Hartmut Land (ICRF, London); and
PA317-M3P-SVHygro was generated in our own laboratories
(Gaken et al., 1992). For infectious viral supernatant,
adherent producer cells grown in DMEM+10% NCS were
transferred to RPMI-1640 + 10% FCS and cell supernatants
collected at a minimum of 4 hourly intervals, filtered
(0.45 ,um filter) and polybrene was added to a final
concentration of 4-8 ig ml-'. B16F10 cells were plated in
RPMI-1640+ 10% FCS until adherent, then filtered viral
supernatant added directly to the cells at 10-20 ml/plate/
round of infection with between four and ten rounds of
infection. Following infection, cells were cultured in fresh
medium (RPMI-1640 + 10% FCS) for a further 72 h before
selection in either 1 mg ml-' G418 (500 jug ml-'), 2 jug ml-'
puromycin, 150 ,ug ml-' hygromycin, or appropriate combi-
nations. Drug-resistant cells were either ring cloned directly
from plates (IL-2/clone 2, IL-4/clone 5), or trypsinised and
frozen as a mixed population (M3P). For infection with both
IL-2 and IL-4, a clone (IL-4/clone 4) was tested for cytokine
secretion, infected with IL-2 viral supernatant, selected and
ring cloned.
The cell lines expressing IL-2, IL-4 and IL-2+IL-4 were
produced using 'pBabe' vectors (see above), and the empty-
vector control transduced cell line used was produced using
the 'M3P' vector (see above). However, as both vectors
contain the same gag sequence the expression of viral protein
in the transduced cell lines will be the same.
Cytokine assays
Cells were trypsinised, counted and added to the 12 wells of a
microtest plate at a density of 1- 1.5 x 105 cells in a final
volume of 4-5 ml per well. Plates were incubated for 24 h
(37°C, 5% carbon dioxide), the medium removed and frozen
(-20°C). For experiments examining the effect of radiation
on the cytokine production of transduced cells, the cells were
adjusted to the correct density (as above), and irradiated
(10 000 rads y-irradiation) before plating and subsequent
incubation.
Levels of cytokine production from transduced cells were
measured using a standard ELISA protocol as follows. High
binding capacity immunoassay strips were coated overnight
at 4°C with coating buffer (0.1 M sodium bicarbonate, pH
8.2) containing 2 Mug ml-' monoclonal anti-cytokine capture
antibody. Following washing (PBS+0.05% Tween-20), the
wells are blocked by incubation for 2 h at 22°C with assay
buffer (PBS/10% FCS) then washed as above. Recombinant
murine IL-2 or IL-4 (dissolved in assay buffer; NIBSC 93/
566, IL-2; 91/656, IL-4) was added to the wells in duplicate
over the range 0-2000 pg ml-'. Following incubation
overnight at 4°C the plates were washed (as above) and a
biotinylated monoclonal anti-cytokine antibody added (in
assay buffer) to each well at a concentration of 1 Mg ml-'.
The plates were incubated for 45 min at 22°C, washed and
avidin-peroxidase (2.5 Mg ml-' in assay buffer) added to the
wells before further incubation for 30 min at 22°C. After
washing, substrate (0.4 mg ml-'O-phenylenediamine in
0.05 M phosphate-citrate buffer with 0.03% sodium
perborate) was added and the plates incubated for 30 min
at 22°C. The reaction was stopped by adding 2 M sulphuric
acid, the optical density (OD) measured at 490 nm and
cytokine production by transduced cells expressed as pg (IL-
2/IL-4) per 106 cells per 24 h.
Tumorigenicity studies/animal experiments
Exponentially growing wild-type and transduced cells were
trypsinised, counted, washed and resuspended in Tyrode's
tissue culture medium minus phenol red (Tyrode's solution;
Gibco, UK). Cells (105 in 200 pl) were injected subcuta-
neously into the flank of either syngeneic C57B1/6 (female,
6-8 weeks old), or sublethally irradiated (300-400 rads y-
irradiation) C.B-171cruCru-SCID (female 6-8 weeks old;
Charles River, UK) mice. For 'treatment' experiments,
animals were injected subcutaneously with wild-type tumour
cells (104 or 105) and when tumours had started to form (2-
5 mm; approximately 7 days later) were treated by a single
injection at a local site of irradiated (10 000 y-rads)
transduced cells (105 or 106). In 'vaccination' experiments,
animals were injected subcutaneously at day zero with 105
irradiated (10 000 y-rads) wild-type or transduced cells, or
Tyrode solution as control. A similar second vaccinating
injection was given in the same site at day 8, and at day 14
animals were challenged by subcutaneous injection (again at
the same site) with 105 live wild-type cells. Animals were
observed every 4 days until tumour formation, after which
the maximum tumour diameter (in mm) was recorded every
2-3 days. Animals were sacrificed when tumours were (i) >
25 mm or 5% of total body weight, or (ii) ulcerating.
Analysis of explanted tumours
B16F10 tumours were explanted, transferred to a Petri dish
containing PBS and disaggregated mechanically. The cell
suspension was washed twice with PBS and plated out in
fresh medium. The expanded adherent monolayer, and fresh
tumour explants were used for further analysis as follows.
(1) Cytokine production: cell supernatants were harvested
and analysed for cytokine production as above.
(2) DNA analysis: genomic DNA was prepared from 107
cultured cells using standard protocols and analysed by
PCR. Nanogram quantities of DNA were amplified
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using primers encompassing the whole of the open
reading frame ofmurine IL-2 or IL-4. Briefly, DNA was
digested using SU SmaI in 10 Ml aliquots, then heated to
95°C for 4 min followed by 35 cycles of 45 s each at 95,
55 and 72°C. Amplified products were electrophoresed
on 1% agarose gel and the amplified IL-2 and IL-4
sequences (arising from cells containing an uninter-
rupted reading frame) gave bands of 510 and 435 bp
respectively.
(3) Histology: tissue from the site of tumour inoculation
and tumour explants was fixed in 10% formal-saline and
embedded in paraffin wax. Haematoxylin- and eosin-
stained sections from frozen tissue blocks were examined
and the number of lymphocytes, granulocytes and
macrophages per 10 high-power fields scored.
Results
Tumorigenicity studies
(1) In vivo growth of cytokine transduced B16F10 cells The
growth of wild-type, empty-vector (M3P), IL-2, IL-4 and IL-
2+ IL-4 transduced B16F10 cells in vivo can be seen in Figure
1. When injected subcutaneously into syngeneic mice, wild-
type B16F0 or empty-vector transduced cells grew rapidly,
forming tumours of 25-30 mm within 20 days. Expression of
IL-2 delayed the onset of tumour formation for approxi-
mately 8-10 days but all animals had formed 25-30 mm
diameter tumours by day 40. Furthermore, once established,
tumours expressing IL-2 grew at a rate comparable with
either the wild-type or empty-vector transduced cells. When
cells expressing IL-4 were injected the initial tumour
formation was further delayed for, on average, 20 days and
the life of animals was prolonged to approximately 80 days.
However, once formed, the subsequent growth of tumours
expressing IL-4 was somewhat slower than the wild-type,
empty-vector or IL-2 transduced cells. When B16F1O cells
were transduced to express combined IL-2 +IL-4 a synergistic
effect was seen with the formation of tumours delayed for at
least 40 days, and in some cases up to 90 days after
inoculation. These tumours, similar to IL-4 alone, once
formed, grew at a slightly slower rate. All animals, despite the
cell line (wild-type, empty-vector, IL-2, IL-4, IL-2+IL-4),
eventually formed tumours that developed to 25-30 mm in
diameter. The in vitro growth characteristics of all cell lines
used in these studies were similar and the levels of cytokine
production remained largely unaltered through repeated
passage in vitro. (data not shown). Furthermore, in 3-4
repeat experiments with 5-10 animals per group, we have
not seen any incidence of spontaneous regression or complete
rejection of any tumour.
(2) Cytokine/molecular analysis of explanted tumours The
eventual formation of tumours might result from a loss of
gene expression, mutation, recombination, translocation, or
deletion of the inserted DNA sequences. Tumours were
explanted at sacrifice, cultured and analysed by ELISA for
cytokine expression, and PCR for the presence of the inserted
DNA sequences. In all cases there was a significant reduction
in the levels of cytokine expression in tumour explants
compared with the original inoculated cells (see Table I).
PCR analysis, using primers encompassing the whole of the
open reading frame of either IL-2 or IL-4, showed that the
inserted DNA sequences were present. In preliminary studies,
in vitro treatment of explanted tumours with 5-azacytidine (4
or 6 gM) restored both the antibiotic resistance, and cytokine
expression to levels similar to the original cell inoculum and
so formation of tumours may be due to methylation of the
retroviral LTR sequences.
(3) Histology Potential immune mechanisms involved in the
arrest of tumour growth while expressing IL-2, IL-4 or IL-
2 + IL-4 were investigated by examining local immune
infiltrates. Wild-type or transduced cells (105) were inocu-
lated subcutaneously and 20-28 days later tumours, or the
site of tumour inoculation if tumours had not yet formed,
were explanted. Sections were stained and scored as described
in Materials and methods. The results of the histological
examination are summarised in Table II. Wild-type tumours
showed a general infiltrate around the main tumour mass
comprising mainly macrophages with few granulocytes.
Tumours secreting IL-2 had an increased infiltration of
granulocytes (417 per 10 high-power fields compared with 63
in the wild type), and similar to the wild type these were
distributed around the main tumour mass. There was an
increase in the numbers of all the types of immune effector
cells scored in tumours secreting IL-4, with the largest
increase seen in the numbers of granulocytes (500 per 10
high-power fields). However, in these sections there were also
more macrophages present (536 compared with 334 in the
wild type) and a few of the granulocytes were localised within
the tumour. When cells secreting combined IL-2+IL-4 were
inoculated there was a large increase in the numbers of
infiltrating granulocytes (1246 per 10 high-power fields) but
little or no change was seen in the numbers of infiltrating
lymphocytes or macrophages. Furthermore, unlike wild-type
tumours or those secreting IL-2 or IL-4 alone, there were
more cells localised within the tumour mass, indicating an
ability of these cells to infiltrate within the tumour.
(4) Growth of B16F10 tumours in SCID mice Wild-type
tumours formed rapidly and all animals had succumbed to
their tumours by day 30 (data not shown). Cells expressing
IL-2, IL-4 or IL-2+IL-4 initiated tumours at the same time.
However, the further growth of tumours expressing IL-2 or
IL-4 was slightly delayed compared with wild-type cells. The
growth of tumours expressing combined IL-2+IL-4 was
delayed further and animals did not succumb to their
tumours until, on average, day 40 (a delay of 10 days).
Analysis of these tumour explants suggested a larger infiltrate
of granulocytes (data not shown).
(5) Local/systemic expression of cytokines To examine
whether the therapeutic benefit ofcombined expression of IL-
2+IL-4 resulted from a local or systemic effect, the in vivo
growth of cells expressing IL-2 and IL-4 alone injected in the
same animal but on opposite flanks was compared with that of
either a clonal population of cells expressing combined IL-
2+ IL-4, or cells expressing single cytokines IL-2 and IL-4
mixed and injected on a single flank. Table III details the
experimental conditions with the levels ofcytokine expression
by thecells injected, and the results are summarised in Figure 2.
The growth of 0.5 x I05 wild-type B16FO0 cells in vivo was
similar to 105 wild-type cells, so within the conditions of our
experiments the initial cell number inoculated had little or no
effect on the rate of tumour growth. Similarly, the growth of
tumours from 0.5 x 105 cells expressing IL-2 or IL-4 alone
was comparable with that of 105 transduced cells (see Figure
2b-d and Table III). When cells expressing IL-2 and IL-4
alone (0.5 x 105 of each cell type) were injected in the same
animals but at distant sites (opposite flanks), the growth of
tumours was similar to that from a single inoculation of 105
cells expressing IL-2 or IL-4 alone (see Figure 2b-d). The
beneficial effects ofcombined IL-2+IL-4 expression probably
result from a local rather than systemic effect. However,
when cells expressing IL-2 and IL-4 alone were mixed (1:1;
0.5 x I05 of each cell type) and injected at the same site the
formation of tumours was characteristic of cells expressing
IL-4 alone rather than combined IL-2 + IL-4 (see Figure 2c,
e, f). Although the local secretion of IL-4 would seem to
affect the growth of tumour cells expressing IL-2 within this
mixed population of cells, the synergistic effects of combined
IL-2+IL-4 expression were not seen as compared with the
clonal population of cells expressing combined IL-2+IL-4
(see Figure 2e,f).
(6) Treatment of established B16FJO tumours As the
expression of combined IL-2 +IL-4 was more beneficialthan either cytokine alone, we further examined the ability of
lethally irradiated tumour cells expressing combined IL-
2 +IL-4 to treat animals with established wild-type tumours.
Lethal irradiation (10 000 rads y-irradiation) of B16F1O
cells expressing combined IL-2 +IL-4 did not abrogate the
expression of either IL-2 or IL-4 for at least 9 days after
irradiation (Table IV). Syngeneic C57B1/6 mice were injected
subcutaneously with either 104 or 105 wild-type B16F1O cells,
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and when tumours had started to form (approximately 7-10
days later), mice were treated with a single injection at a local
site (same flank) with either 10 or 106 lethally irradiated
wild-type, empty-vector, or combined IL-2+IL-4 transduced
cells. The survival of treated animals can be see in Figure 3a.
Untreated animals formed tumours of 25-30 mm within 20
days. Treatment with irradiated empty-vector transduced cells
had little or no effect on survival (data not shown). When
2
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Figure 1 The growth of wild-type, empty-vector (M3P), IL-2, IL-4 and IL-2+IL-4 transduced B16F1O tumour cells. Syngeneic
C57B1/6 (female, 6-8 weeks old) mice were injected subcutaneously with 105 exponentially growing cells (n =5-10 per group).
Animals were monitored weekly until tumour formation, after which the maximum tumour diameter was recorded every 2-3 days.
Animals were culled if: (i) maximum tumour diameter > 25mm, (ii) tumours > 5% total body weight, or (iii) tumours ulcerated.
The growth for each tumour in a typical experiment is shown. Repeat experiments with 5-10 animals per group produced similar
results.
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Table I Cytokine secretion of parental, IL-2, IL-4 and IL-2+IL-4
transduced B16F10 cells before inoculation, and after tumour
explant
Cell line Before inoculation Tumour explant
Secretion ofIL-2 pg106 cells 24h-1
IL-2 9478+ 1166 437+ 393; ND
IL-2+IL-4 30284±3985 ND; ND
Secretion ofIL-4pg 106 cells 24h-1
IL-4 83823+5433 1549+ 194; 31±98; ND
IL-2+IL-4 47767+4409 ND; ND
Syngeneic C57B1/6 mice were inoculated subcutaneously with 105
exponentially growing parental or transduced cells. Tumours were
explanted at sacrifice according to the criteria set out in Materials and
methods. The secretion of IL-2 and IL-4 by parental and transduced
cells, and tumour explants was assayed as described in Materials and
methods. Values are means+s.d. of triplicate experiments corrected
against a blank of RPMI-1640+10% FCS. ND, below the level of
detection.
tumour-bearing animals were treated with irradiated com-
bined IL-2+IL-4 transduced cells, 60% of animals were
cured of their tumours and remained tumour-free for at least
100 days. In addition, there was a reduced rate of tumour
growth (compared with the wild-type) in the 40% of animals
that did not reject their tumours with combined IL-2+IL-4
treatment (Figure 3b). When tumour-bearing animals were
treated with irradiated wild-type cells, 40% also rejected their
tumours and remained tumour-free for at least 100 days. It is
important to note that whereas B16F1O cells are believed to
be poorly immunogenic as defined by the lack of host
response to live tumour challenge following prior vaccination
with lethally irradiated wild-type cells, these cells are clearly
antigenic, able to stimulate some host response to live tumour
when treated after live tumour challenge with lethally
irradiated wild-type cells. However, when successfully
treated animals were challenged with a second inoculation
of 105 wild-type cells, only the group treated with
combination IL-2+IL-4 were protected against this second
tumour challenge (see Figure 3a; these animals remained
disease free after rechallenge for the duration of the
experiment -240 days). Treatment with irradiated wild-type
cells did not induce a systemic immunity.
(7) Vaccination studies The results of the vaccination
studies are summarised in Figure 4. Animals were vaccinated
twice at a 1 week interval with lethally irradiated wild-type or
IL-2+IL-4 transduced cells, or Tyrode's solution as control.
Vaccinated animals were then challenged with live wild-type
cells. Vaccination with either wild-type or IL-2+IL-4-
expressing cells did not protect against a subsequent wild-
type tumour challenge; Tyrode's vaccinated animals had all
succumbed to their tumours by day 31, 17 days post
challenge; wild-type vaccinated animals by day 35, 21 days
post challenge; IL-2+IL-4-vaccinated animals by day 42, 28
days post challenge. The lack of host response to this
vaccination is consistent with the poor immunogenicity of
this cell line (see Discussion), and transduction to express IL-
2+IL-4 seems to have little or no effect on this
immunogenicity.
Discussion
An increasing number of studies have demonstrated the anti-
tumour effects of cytokine gene transduced autologous
tumour cells. Perhaps the most extensively examined to date
have been the genes for IL-2 and IL-4 (see review by
Table II Characterisation of immune cell infiltrates in explanted tumours. A summary of the morphological analysis of
infiltrating immune cells in tumour explants, prepared as described in Materials and methods. Values are absolute
numbers
B16F1O tumour
Wild-type IL-2 IL-4 IL-2+IL-4
Haematoxylin and eosin
Macrophages 334 275 536 356
Lymphocytes 137 104 200 120
Granulocytes 63 417 500 1246
Total 534 796 1236 1722
Table III Cytokine secretion and tumour cell inoculum per animal of experiment to examine the effects of local and systemic secretion of
cytokines on the tumorigenicity of B16FIO cells
Cytokine expression
Experiment Cell inoculation (pg 1J_6 cells 24h-1)
(cell line) Flank (cell no.) IL-2 IL-4
Wild-type L 105 959 1720
R
Wild-type L 0.5 x 105 480 860
R 0.5 x 105 480 860
IL-2 L 105 9478 -
R
IL-4 L 105 83823
R
IL-2/IL-4 L 0.5 x 105 IL-2 4739 -
R 0.5x 105 IL-4 - 41912
IL-2+IL-4 L 0.5 x 105 IL-2+0.5 x 105 IL-4 4739 41912
Mix R - - -
IL2 +IL-4 L 105 30284 47767
Clone R
The results are summarised in Figure 3. The levels ofcytokine secretion were assayed as described in Materials and methods, and values are the
mean oftriplicate experiments.Colombo and Forni, 1994). In the weakly immunogenic
murine fibrosarcoma cell line CMS-5 (Gansbacher et al.,
1990a) and the transplantable rat sarcoma HSNLV (Russel et
al., 1991) there was a reduced tumorigenicity and induction
of protective immunity in animals injected with tumour cells
transduced with a cDNA encoding human IL-2. Similar
effects have been reported using murine IL-2 in the poorly
immunogenic CT26 murine colon cancer cell line (Fearon et
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al., 1990), and murine IL-4 in Renca cells (Golumbek et al.,
1991) and the weakly immunogenic murine fibrosarcoma
FS29 (Patel et al., 1993). Most of these studies suggest a
direct relationship between levels of cytokine expression and
therapeutic benefit. In practice, although transducing cells to
express cytokine genes is relatively straightforward, obtaining
clones expressing high levels of the transfected gene may not
be as easy, especially for clinical application. Increased
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Figure 2 The growth of wild-type and cytokine transduced B16FO0 tumour cells to compare the local and systemic effects of IL-2
and IL-4 expression on tumorigenicity. Syngeneic C57B1/6 (female, 6-8 weeks old) mice were injected subcutaneously with 105
exponentially growing cells (n=5-10 per group). Animals were monitored according to the criteria set out in Materials and
methods, and the experimental details and levels ofcytokine expression are summarised in Table III. The growth for each tumour in
a typical experiment is shown. Cell inoculations were as follows (a) 105 wild-type, left flank: (b) 10 IL-2, left flank; (c) 105 IL-4, left
flank; (d) 0.5 x 105 IL-2, left flank, 0.5 x 105 IL-4, right flank; (e) 0.5 x 105 IL-2 +0.5 x 105 IL-4 (mix), left flank; (f) 105 IL-2 + IL-4
(clone), left flank.
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Table IV Cytokine secretion ofparental, IL-2, IL-4 and IL-2+IL-4 transduced B16F10 cells before and after lethal irradiation (10 000 y-rads)
Days after irradiation
Cell line Irradiation 1 3 6 9
Secretion ofIL-2pg 1076 cells 24h-1
Parental 959 906 - - -
IL-2 6612 4744 18591 4131 2564
IL-2+IL-4 13900 10994 32857 18040 5135
Secretion ofIL-4pg 107 cells 24h-1
Parental 1720 1408
IL-4 135685 147330 303925 34150
IL-2+ IL-4 128912 54530 243625 112163
The levels ofcytokine secretion were assayed as described in Materials and methods. Values are the mean oftriplicate experiments.
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Figure 3 Treatment of established wild-type B16FIO tumours
with lethally irradiated combined IL-2+IL-4-expressing auto-
logous tumour cells. Syngeneic C57BI/6 (female, 6-8 weeks old)
mice were inoculated subcutaneously with exponentially growing
wild-type B16F10 cells (n =5-10 per group). When tumours had
started to form animals were treated at a local site with lethally
irradiated (10000 y-rads) wild-type or transduced cells. Animals
were monitored according to the criteria set out in Materials and
methods, and those surviving disease free at day 110 were
rechallenged by a subcutaneous injection (on the same flank as
treatment was given) of 105 exponentially growing B16F10 wild-
type cells. The experiment shown is for an inoculation (I) of 105
cells with a treatment (T) of 106 cells. (a) percentage overall
survival. (b) Growth of tumours in animals not successfully
treated (i.e. 40% of the combined IL-2+IL-4 treatment group,
and 60% of the wild type treatment group-see (a). Repeat
experiments with n=5-10 animals per group have produced
similar results.
Figure 4 Vaccination of animals with lethally irradiated wild-
type or combined IL-2 +IL-4-expressing cells induced little or no
protection against a subsequent live wild-type tumour challenge.
Syngeneic C57B1/6 (female, 6-8 weeks old) mice were inoculated
(I) subcutaneously twice at a 1 week interval with 105 lethally
irradiated (10000 y-rads) wild-type or transduced cells, or
Tyrode's solution as control (n=5-10 per group). One week
following the second vaccination, animals were challenged (C)
with 10 exponentially growing parental wild-type cells. Animals
were monitored according to the criteria set out in Materials and
methods. Repeat experiments with n=5-10 animals per group
have produced similar results.
benefit may be observed if a synergistic effect occurs with
multiple cytokine gene transduction. Few previous studies
have examined the therapeutic effects of multiple cytokine
gene transduction of tumour cells.
In the present study, transduction of B16FIO cells to
express IL-4 reduced tumorigenicity more than IL-2,
confirming the work of others (Patel et al., 1993). However,
expression of combined IL-2+IL-4 delayed tumour forma-
tion considerably further. Cytokine expression appears to
arrest tumour growth by stimulating a local infiltrate of non-
specific immune effector cells. Expression of IL-2 alone
caused an increase in granulocyte infiltrates, although Patel et
al., (1993) reported the infiltrate in IL-2-transduced FS29
tumours to be largely CD8+ lymphocytes. Transduction of
B16FIO cells to express IL-4 caused an increased infiltrate of
both granulocytes and macrophages. Similar infiltrates have
been seen by others in IL-4-transduced tumours (murine
plasmacytoma and murine adenocarcinoma, Tepper et al.,
1989; murine renal cell carcinoma, Golumbek et al., 1991;
murine fibrosarcoma, Patel et al., 1993). Combined expres-
sion of IL-2+IL-4 produced a greater increase in the total
number of infiltrating granulocytes, although there were
fewer infiltrating macrophages than with IL-4 alone.
Furthermore, in contrast to either cytokine alone, many of
the granulocytes in the IL-2 + IL-4 tumours were actually
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localised within the tumour rather than on the periphery.
Combined IL-2 +IL-4 could increase the expression of
adhesion molecules (ICAM, VCAM) thus facilitating
tumour infiltration by immune effector cells (Verdegaal et
al., 1993). The previously demonstrated inhibition of tumour
rejection in the presence of anti-granulocyte antibodies
indicates the importance of the granulocyte infiltrate
(Tepper et al., 1992). However, all animals eventually
formed tumours and, in contrast to other reports where
tumour formation results from loss of the transgene (Russell
et al., 1991; Patel et al., 1993), our results suggest that the
eventual formation of tumours may be due to inactivation of
the cytokine gene expression by methylation of the retroviral
LTR sequences. It remains consistent however that while the
transgene is being expressed protection against tumour
growth is offered. Histological examination of 'fully-formed'
IL-2, IL-4 or IL-2 + IL-4 tumours shows an immune infiltrate
characteristic of wild-type tumours, suggesting that loss of
cytokine gene expression reduces the stimulus for immune
effector cells to infiltrate locally, and so leads to tumour
formation.
When cells expressing IL-2 or IL-4 alone were admixed
with parental wild-type cells, little or no delay in tumour
formation was seen (data not shown). Patel et al. (1993)
reported similar observations with FS29 cells, although these
results contrast with other reported studies of tumour cells
secreting IL-2 (Gansbacher et al., 1990a; Ley et al., 1991) or
IL-4 (Tepper et al., 1989; Golumbek et al., 1991). Similarly,
in the present study, cells expressing combined IL-2+IL-4
had no beneficial effect when mixed with wild-type cells. This
may reflect the levels ofcytokine expression by the cells used,
and thus their ability to stimulate an inflammatory response,
or a difference in the immunogenicity of the cell line used.
However, in our experiments cells were mixed in the ratio 1:1
of transduced cells -wild type cells and in separate
experiments we saw little or no difference in the time to
tumour formation or tumour growth. Thus, there was clearly
a strong selective pressure for the wild-type cells to grow and
predominate, perhaps due to secretion of immunosuppressive
factors such as transforming growth factor (TGF)-# by the
wild-type cells. This might also explain the eventual
formation of tumours. Combined expression of IL-2+IL-4
may counteract the immunosuppressive factors normally
produced by the tumour cells, however, when cytokine
expression is lost there is a change in the levels of cytokine
expression relative to the production of immunosuppressive
factors and so the tumour develops.
Lethally irradiated cells expressing combined IL-2+IL-4
were able to treat a subgroup of tumour-bearing animals and
induce a systemic immunity, the effect presumably mediated by
stimulation of a local non-specific immune infiltrate. Similar
findings have beenreportedwith renalcarcinomacells secreting
IL-4 (Golumbek et al., 1991) and avariety ofcells secreting IL-
2 (Fearon et al., 1990; Gansbacher et al., 1990a; Ley et al.,
1991), although the duration and extent ofprotection has been
varied. In contrast, plasmacytoma cells transduced to express
IL-4 were unable to elicit the same host response (Tepper et al.,
1992). In the studies of Golumbek et al., (1991) successful
treatment with cellsexpressing IL-4 occurred onlywhen a small
number ofparentalwild-type cells werepreinjected. Patel et al.,
(1993) reported an increased protection against wild-type
tumour challenge for at least 30 days in 40% of animals
following excision of a primary tumour. However, although
these results look encouraging, the initial tumour inoculation
was of cells expressing IL-4 rather than wild-type cells and
various reports have demonstrated protectionagainstwild-type
challenges following prior exposure to cytokine transduced
tumour cells (Fearon et al., 1990; Gansbacher et al., 1990a;
Golumbek et al., 1991; Ley et al., 1991). Induction of a
protective immunity requires T-cell stimulation. The inflam-
matory infiltrate stimulated by expression of combined IL-
2 + IL-4 (see Table II) was granulocytic with little or no effect
on lymphocyte infiltration. Furthermore, the eventual forma-
tion of tumours secreting combined IL-2 + IL-4 might also
argue against a direct T-cell involvement. However, treatment
of established tumours with combined IL-2+ IL-4 induced a
protective immunity. Rejection oftumours can be due to direct
killing by activated granulocytes (eg. neutrophils, eosinophils),
whereas the induction and effector phases of memory require
involvement of CD4+ and CD8+ cells (Colombo and Forni,
1994). When tumour cells are engineered to express cytokines,
the levels of cytokine released correlate with the intensity of
tumour rejection. Colombo and Forni (1994) suggest that high
levels of cytokine lead to the rapid disappearance of the
tumour, which results in insufficient loading of antigen-
presenting cells and so the memory effect is not induced.
However, lower amounts ofcytokines induce a slower reaction
in which initial growth is followed by rejection, and so a
significant amount of tumour-cell debris becomes available to
antigen-presenting cells both in the tumour rejection site and
the draining lymphnodes that have activeT-cell areas. Thus, by
an initial non-specific inflammatory reaction a systemic
immunity may be induced, and this most likely explains the
results we have obtained. Despite this, vaccination with lethally
irradiated IL-2+IL-4-expressing cells did not induce immune
protection against a subsequent challenge with live wild-type
tumour (see Figure 4). However, this may be explained by a
difference in the nature and extent of initial non-specific
immune infiltration.
Lethally irradiated wild-type cells successfully treated 40%
of tumour-bearing animals. Many published studies do not
report the effects when wild-type cells are used for treatment.
The response of host to tumour can vary according to prior
exposure/treatment with wild-type tumour alone (Hewitt et
al., 1976; Colombo and Forni, 1994); the immunogenicity of
a tumour cell line is defined as the host response to live
tumour challenge following prior vaccination with lethally
irradiated wild-type cells. This, however, does not indicate the
potential antigenicity of a particular tumour cell line. In our
vaccination studies, neither wild-type nor IL-2+IL-4-expres-
sing cells were able to protect against live wild-type tumour
challenge. However, in our treatment studies both cell lines
were able to cure a subpopulation of animals with established
tumours, albeit to differing extents. Thus, whereas B16F1O
cells may be poorly immunogenic, by the above criteria they
are antigenic. Furthermore, this antigenicity would seem to
be further enhanced by the expression ofcombined IL-2 +IL-
4 as there was a greater cure rate in tumour-bearing animals
when treatment was with combined IL-2+IL-4-expressing
cells compared with wild-type cells. Thus the immunogenicity
and antigenicity of a tumour cell line must be separately
addressed. Animals cured of established tumours by
treatment with lethally irradiated combined IL-2+IL-4-
expressing cells were protected against a further challenge
with live wild-type cells. In contrast, successful treatment with
lethally irradiated wild-type cells offered no such protection.
The mechanism underlying the difference in response
compared with combined IL-2+IL-4 treatment is unclear
but may reflect a difference in the nature of the initial
immune infiltrate due perhaps to the relative antigenicity, or
alternatively, insufficient loading ofantigen-presenting cells to
induce T-cell activation in the draining lymph nodes.
Cells expressing IL-2 alone mixed with cells expressing
IL-4 alone did not produce the same effect as a clonal
population of cells expressing combined IL-2 +IL-4. The
level of IL-2 expression in the combined IL-2+ IL-4-
expressing cells was greater than that in the mixed
population (see Table III) and this may in part explain
the difference in the effects seen. However, the rate of
growth of tumours from the mixed cell population was
characteristic of IL-4 alone, indicating that the local
secretion of IL-4 can affect cells expressing IL-2, and in
contrast to cells expressing combined IL-2+IL-4, the mixed
population of cells showed no synergistic effect. Further-
more, our results and those of others (Tepper et al., 1989;
Golumbek et al., 1991; Patel et al., 1993) suggest that IL-4
is the more effective cytokine in stimulating granulocytic
infiltrates (which elicit the greatest effect in the initialL-2+IL4 gene Ohrpy of B16 m %:9 SJ Hoilkngsworth et al
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immune cell infiltrate crucial in the response to tumour).,
with IL-9 producing only a hmited effect. When combined
IL-2 + IL-4-expressing cells were injected the increased
infiltrate was almost exclusively granulocytic, so it seems
unlikely that the increased expression of IL-2 in these cells
is providing an additional stimulus for a non-specific
inflammatory response above that seen with IL-2 alone.
In studies using the CMS5 fibrosarcoma, Salvadonr et al..
(1994) suggest that IL-2 secretion by tumours prevents
immunosuppression in tumour-bearing mice by maintaining
normal signal transduction in T cells so facilitating the
generation of an anti-tumour response. Tumour-derived IL-
2 seems to function by directly activating p56"k associated
with the IL-2 receptor #-chain decreasing the susceptibility
of CD8 cells to inactivation signals delivered by tumour
cells. However, in our studies the effect of IL-2 +IL-4
expression appears to be mediated by granulocytes rather
than lymphocytes. Our results clearly suggest that transduc-
tion of tumour cells to express both IL-2+ IL-4 results in a
synergistic action between the cytokines that is of greater
therapeutic benefit than transduction with either cytokine
alone.
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